The systemic effects of platelet-rich plasma injection

American Journal of Sports Medicine

Volumn 41, Issue 1, 2013, Pages 186-193

  Wasterlain, Amy S ^a   Braun, Hillary J ^a   Harris, Alex H S ^a   Kim, Hyeon Joo ^a   Dragoo, Jason L ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Athletic performance; Doping in sports; Growth factors; Human growth hormone; Insulin like growth factor 1; Platelet rich plasma

Indexed keywords

BIOLOGICAL MARKER; SIGNAL PEPTIDE;

ADULT; ARTICLE; BLOOD; DOPING; FEMALE; HUMAN; MALE; MIDDLE AGED; THROMBOCYTE RICH PLASMA;

ADULT; BIOLOGICAL MARKERS; DOPING IN SPORTS; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; PLATELET-RICH PLASMA;

MLCS; MLOWN;

EID: 84878598980     PISSN: 03635465     EISSN: 15523365     Source Type: Journal    
DOI: 10.1177/0363546512466383     Document Type: Article

References (35)

1. Anitua E, Sanchez M, Nurden AT, et al. Autologous fibrin matrices: a potential source of biological mediators that modulate tendon cell activities. J Biomed Mater Res A. 2006;77(2):285-293.
2. Banfi G, Corsi MM, Volpi P. Could platelet rich plasma have effects on systemic circulating growth factors and cytokine release in orthopaedic applications? Br J Sports Med. 2006;40(10):816.
3. Barton-Davis ER, Shoturma DI, Musaro A, Rosenthal N, Sweeney HL. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci USA. 1998;95(26):15603- 15607.
4. Blair JC, Camacho-Hubner C, Miraki Moud F, et al. Standard and low-dose IGF-I generation tests and spontaneous growth hormone secretion in children with idiopathic short stature. Clin Endocrinol (Oxf). 2004;60(2):163-168, discussion 161-162.
5. Bouhours-Nouet N, Gatelais F, Boux De Casson F, Rouleau S, Coutant R. The insulin-like growth factor-l response to growth hormone is increased in prepubertal children with obesity and tall stature. J Clin Endocrinol Metab. 2007;92(2):629-635.
6. Castillo TN, Pouliot MA, Kim HJ, Dragoo JL. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. Am J Sports Med. 2011;39(2):266-271.
7. Cook DR, Doumit ME, Merkel RA. Transforming growth factor-beta, basic fibroblast growth factor, and platelet-derived growth factor-BB interact to affect proliferation of clonally derived porcine satellite cells. J Cell Physiol. 1993;157(2):307-312.
8. Creaney L, Hamilton B. Growth factor delivery methods in the management of sports injuries: the state of play. Br J Sports Med. 2008;42(5):314-320.
9. Dall R, Longobardi S, Ehrnborg C, et al. The effect of four weeks of supraphysiological growth hormone administration on the insulinlike growth factor axis in women and men: GH-2000 Study Group. J Clin Endocrinol Metab. 2000;85(11):4193-4200.
10. Daughaday WH, Rotwein P. Insulin-like growth factors I and II: peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev. 1989;10(1):68-91.
11. Dragoo JL, Braun HJ, Durham JL, et al. Comparison of the acute inflammatory response of two commercial platelet-rich plasma systems in healthy rabbit tendons. Am J Sports Med. 2012;40(6):1274-1281.
12. Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg. 2004;114(6):1502-1508.
13. ErythroSave. Snapshot of PRP markets (US). Available at: http://www.erythrosave.net/index.php?option=com-content&task=view&id= 15<emid=29. Accessed June 26, 2012.
14. Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med. 2009;37(11):2259-2272.
15. Gosens T, Peerbooms JC, Van Laar W, Den Oudsten BL. Ongoing positive effect of platelet-rich plasma versus corticosteroid injection in lateral epicondylitis: a double-blind randomized controlled trial with 2-year follow-up. Am J Sports Med. 2011;39(6):1200-1208.
16. Gustafsson T, Kraus WE. Exercise-induced angiogenesis-related growth and transcription factors in skeletal muscle, and their modification in muscle pathology. Front Biosci. 2001;6:D75-D89.
17. Harrison S, Vavken P, Kevy S, Jacobson M, Zurakowski D, Murray MM. Platelet activation by collagen provides sustained release of anabolic cytokines. Am J Sports Med. 2011;39(4):729-734.
18. Jackson JR, Minton JA, Ho ML, Wei N, Winkler JD. Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1beta. J Rheumatol. 1997;24(7):1253-1259.
19. Kniess A, Ziegler E, Kratzsch J, Thieme D, Muller RK. Potential parameters for the detection of hGH doping. Anal Bioanal Chem. 2003;376(5):696-700.
20. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis:2001. Endocr Rev. 2001;22(1):53-74.
21. Lee PD, Durham SK, Martinez V, Vasconez O, Powell DR, Guevara-Aguirre J. Kinetics of insulin-like growth factor (IGF) and IGF-binding protein responses to a single dose of growth hormone. J Clin Endocrinol Metab. 1997;82(7):2266-2274.
22. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246(4935):1306-1309.
23. Mauras N, Haymond MW. Are the metabolic effects of GH and IGF-I separable? Growth Horm IGF Res. 2005;15(1):19-27.
24. Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med. 2006;34(11):1774-1778.
25. Peerbooms JC, Sluimer J, Bruijn DJ, Gosens T. Positive effect of an autologous platelet concentrate in lateral epicondylitis in a doubleblind randomized controlled trial: platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. Am J Sports Med. 2010;38(2):255-262.
26. Schmidmaier G, Herrmann S, Green J, et al. Quantitative assessment of growth factors in reaming aspirate, iliac crest, and platelet preparation. Bone. 2006;39(5):1156-1163.
27. Spiliotis BE, Alexandrides TK, Karystianos C, et al. The insulin-like growth factor-l (IGF-I) generation test as an indicator of growth hormone status. Hormones (Athens). 2009;8(2):117-128.
28. Sundman EA, Cole BJ, Fortier LA. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. Am J Sports Med. 2011;39(10):2135-2140.
29. Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. Br J Pharmacol. 2008;154(3):557-568.
30. Volpi P, Quaglia A, Schoenhuber H, et al. Growth factors in the management of sport-induced tendinopathies: results after 24 months from treatment. A pilot study. J Sports Med Phys Fitness. 2010;50(4):494-500.
31. World Anti-Doping Agency (WADA). The World Anti-Doping Code: The 2013 Prohibited List, International Standard. Montreal: WADA; 2013.
32. Walenkamp MJ, Wit JM. Genetic disorders in the GH IGF-I axis in mouse and man. Eur J Endocrinol. 2007;157 Suppl 1:S15-S26.
33. Wallace JD, Cuneo RC, Baxter R, et al. Responses of the growth hormone (GH) and insulin-like growth factor axis to exercise, GH administration, and GH withdrawal in trained adult males: a potential test for GH abuse in sport. J Clin Endocrinol Metab. 1999;84(10):3591-3601.
34. Wasterlain AS, Braun HJ, Dragoo JL. Contents and formulations of platelet-rich plasma. Oper Techn Orthop. 2012;22(1):33-42.
35. Wilting J, Christ B, Bokeloh M, Weich HA. In vivo effects of vascular endothelial growth factor on the chicken chorioallantoic membrane. Cell Vssue Res. 1993;274(1):163-172.